AC Immune rises on interim mid-stage data for Parkinson's therapy

AC Immune SA

14/11/2024 12:40

** Shares of Switzerland-based drug developer AC Immune
 ACIU.O  rise 8.3% to $3.39 premarket
    ** Company's experimental immunotherapy to treat early
Parkinson's disease was well tolerated with no clinically
relevant safety issues, it says citing interim data from a
mid-stage study
    ** Parkinson's disease is a progressive movement disorder of
the nervous system, which causes nerve cells in parts of the
brain to weaken, become damaged and die
    ** The therapy, ACI-7104.056, induced high immune response
on average 16-fold higher than placebo after 3 immunizations
-ACIU
    ** Company plans to share further data from the study in H1
2025
    ** Data includes analyses from over 30 patients randomized
to receive ACI-7104.56 or placebo at a ratio of 3:1 - ACIU
    ** Up to last close, stock down ~37% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com))